Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:COAG NASDAQ:FATE NASDAQ:HROW NASDAQ:OCS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCOAGHemab Therapeutics$26.39-3.9%$0.00$23.00▼$36.61$1.23BN/A216,989 shs121,554 shsFATEFate Therapeutics$2.25-12.5%$1.64$0.91▼$2.88$262.84M2.532.32 million shs5.06 million shsHROWHarrow$32.74-0.4%$36.02$27.75▼$54.85$1.22B0.28749,693 shs370,876 shsOCSOculis$13.19+7.3%$27.46$11.70▼$34.47$764.81M0.23472,034 shs1.05 million shs10 Stocks Set to Soar in 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCOAGHemab Therapeutics+1.25%-1.33%-19.21%+2,746,999,900.00%+2,746,999,900.00%FATEFate Therapeutics-6.20%+19.53%+67.97%+77.24%+97.69%HROWHarrow-3.66%-3.83%-19.66%-16.22%+9.61%OCSOculis-15.30%-58.94%-55.28%-55.66%-36.06%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCOAGHemab Therapeutics$26.39-3.9%$0.00$23.00▼$36.61$1.23BN/A216,989 shs121,554 shsFATEFate Therapeutics$2.25-12.5%$1.64$0.91▼$2.88$262.84M2.532.32 million shs5.06 million shsHROWHarrow$32.74-0.4%$36.02$27.75▼$54.85$1.22B0.28749,693 shs370,876 shsOCSOculis$13.19+7.3%$27.46$11.70▼$34.47$764.81M0.23472,034 shs1.05 million shs10 Stocks Set to Soar in 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCOAGHemab Therapeutics+1.25%-1.33%-19.21%+2,746,999,900.00%+2,746,999,900.00%FATEFate Therapeutics-6.20%+19.53%+67.97%+77.24%+97.69%HROWHarrow-3.66%-3.83%-19.66%-16.22%+9.61%OCSOculis-15.30%-58.94%-55.28%-55.66%-36.06%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCOAGHemab Therapeutics 2.80Moderate Buy$41.7558.20% UpsideFATEFate Therapeutics 2.29Hold$5.13127.98% UpsideHROWHarrow 2.64Moderate Buy$69.43112.09% UpsideOCSOculis 2.80Moderate Buy$38.33190.65% UpsideCurrent Analyst Ratings BreakdownLatest FATE, OCS, HROW, and COAG Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/3/2026OCSOculis JPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$42.00 ➝ $23.006/1/2026OCSOculis Robert W. BairdSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$49.00 ➝ $38.006/1/2026OCSOculis Stifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$50.00 ➝ $40.006/1/2026OCSOculis GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$75.00 ➝ $45.006/1/2026OCSOculis HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$47.00 ➝ $26.006/1/2026OCSOculis Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$46.00 ➝ $38.005/27/2026COAGHemab Therapeutics Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold5/26/2026COAGHemab Therapeutics Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$39.005/26/2026COAGHemab Therapeutics The Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$36.005/26/2026COAGHemab Therapeutics Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$39.005/26/2026COAGHemab Therapeutics The Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$36.00(Data available from 6/3/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCOAGHemab TherapeuticsN/AN/AN/AN/AN/AN/AFATEFate Therapeutics$6.65M39.40N/AN/A$1.80 per share1.25HROWHarrow$272.30M4.48$0.83 per share39.47$1.41 per share23.22OCSOculisN/AN/AN/AN/A$4.08 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCOAGHemab TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AN/AFATEFate Therapeutics-$136.32M-$1.09N/AN/AN/A-2,056.79%-58.89%-39.39%8/11/2026 (Estimated)HROWHarrow-$5.14M-$0.41N/A15.16N/A-5.57%19.59%2.26%8/10/2026 (Estimated)OCSOculis-$119.44M-$2.13N/AN/AN/A-8,460.67%-56.78%-45.62%8/6/2026 (Estimated)Latest FATE, OCS, HROW, and COAG EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/21/2026Q1 2026COAGHemab TherapeuticsN/A-$23.98N/A-$23.98N/AN/A5/13/2026Q1 2026FATEFate Therapeutics-$0.29-$0.26+$0.03-$0.26$1.49 million$1.30 million5/11/2026Q1 2026HROWHarrow-$0.43-$0.74-$0.31-$0.74$52.43 million$44.20 million5/8/2026Q1 2026OCSOculis-$0.49-$0.63-$0.14-$0.61$0.25 million$0.26 million3/3/2026Q4 2025OCSOculis-$0.43-$0.51-$0.08-$0.51$0.14 million$0.50 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCOAGHemab TherapeuticsN/AN/AN/AN/AN/AFATEFate TherapeuticsN/AN/AN/AN/AN/AHROWHarrowN/AN/AN/AN/AN/AOCSOculisN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCOAGHemab TherapeuticsN/AN/AN/AFATEFate TherapeuticsN/A5.855.85HROWHarrow10.302.482.30OCSOculis0.015.185.18Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCOAGHemab TherapeuticsN/AFATEFate Therapeutics97.54%HROWHarrow72.76%OCSOculis22.30%Insider OwnershipCompanyInsider OwnershipCOAGHemab TherapeuticsN/AFATEFate Therapeutics4.74%HROWHarrow12.80%OCSOculisN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCOAGHemab Therapeutics7246.71 millionN/AN/AFATEFate Therapeutics550116.56 million111.03 millionOptionableHROWHarrow18037.28 million32.50 millionOptionableOCSOculis257.98 millionN/ANot OptionableFATE, OCS, HROW, and COAG HeadlinesRecent News About These CompaniesINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Oculis Holding AG - OCSJune 2 at 4:59 PM | globenewswire.comOculis shifts focus after phase III DME disappointmentJune 2 at 12:21 PM | bioworld.comBOculis Holding: Study Setback For Eye Drop Therapy Suggests Hold RatingJune 2 at 12:21 PM | seekingalpha.comOculis Holding AG Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information about Potentially Recovering Their LossesJune 2 at 11:23 AM | globenewswire.comOCS SHAREHOLDER INVESTIGATION: SueWallSt Investigates Oculis Holding AG for Possible Securities Law ViolationsJune 2 at 9:00 AM | prnewswire.comOculis Holding AG Investigation Initiated: Levi & Korsinsky Investigates the Officers and Directors of Oculis Holding AG (OCS)June 1 at 3:31 PM | prnewswire.comOCS ALERT: Levi & Korsinsky Investigates Oculis Holding AG for Possible Securities Fraud ViolationsJune 1 at 12:30 PM | markets.businessinsider.comOCS ALERT: Levi & Korsinsky Investigates Oculis Holding AG for Possible Securities Fraud ViolationsJune 1 at 12:05 PM | newsfilecorp.comNOculis Shelves FDA Filing After Phase 3 DME Trials Miss Key Vision GoalsMay 31 at 5:02 PM | marketbeat.comOculis (NASDAQ:OCS) Sees Large Volume Increase - What's Next?May 31 at 4:16 AM | americanbankingnews.comOculis falls on late-stage trial setback for eye therapyMay 30, 2026 | msn.comOCS Stock Drops Over 23% — Eye Drop Trial For Diabetic Vision Loss Misses TargetMay 30, 2026 | finance.yahoo.comOculis Publishes Notifications of Transactions by Persons Discharging Managerial ResponsibilitiesMay 29, 2026 | globenewswire.comOculis Announces Phase 3 Trial Results for OCS-01 Eye Drops in Diabetic Macular Edema, Shifts Focus to Other Development ProgramsMay 29, 2026 | quiverquant.comQOculis Announces Topline Results from DIAMOND Phase 3 Trials with OCS-01 in Diabetic Macular EdemaMay 29, 2026 | globenewswire.comOculis Publishes Notifications of Transactions by Persons Discharging Managerial ResponsibilitiesMay 28, 2026 | globenewswire.comGuggenheim initiates coverage of Oculis Holding (OCS) with buy recommendationMay 22, 2026 | msn.comOculis Holding (OCS) Gets a Buy from LifeSci CapitalMay 17, 2026 | theglobeandmail.comOculis Publishes Notifications of Transactions by Persons Discharging Managerial ResponsibilitiesMay 15, 2026 | globenewswire.comOculis Publishes Results of 2026 Annual General Meeting and Announces Election of Gregory D. ...May 15, 2026 | messenger-inquirer.comMOculis Publishes Results of 2026 Annual General Meeting and Announces Election of Gregory D. Perry to its Board of DirectorsMay 15, 2026 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeFATE, OCS, HROW, and COAG Company DescriptionsHemab Therapeutics NASDAQ:COAG$26.39 -1.08 (-3.93%) As of 02:28 PM EasternWe are a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience. Our mission is to build the leading coagulation company by discovering, developing, and commercializing innovative therapies for the millions of patients worldwide suffering from serious bleeding and thrombotic diseases. Coagulation disorders encompass a broad and heterogeneous group of conditions, and many patients experience significant life-long disease burden due to either a lack of available prophylactic therapies or limitations associated with existing treatment approaches. Our lead asset, sutacimig (HMB-001), is a bispecific antibody currently in Phase 1/2 clinical development for the prophylactic treatment of Glanzmann thrombasthenia and Phase 2 clinical development for the prophylactic treatment of Factor VII deficiency. Our second clinical-stage asset, HMB-002, is a monovalent antibody in Phase 1/2 clinical development for the subcutaneous prophylactic treatment of Von Willebrand Disease. We are also advancing multiple preclinical and discovery-stage assets. We estimate that there are approximately an aggregate of 10,000 patients with Glanzmann thrombasthenia and Factor VII deficiency and an aggregate of 120,000 patients with Von Willebrand Disease in the geographies where we intend to commercialize our assets, including the United States, the European Union, Japan, the Gulf Cooperation Council countries and other select regions. With greater disease burden awareness, potential regulatory approvals of new prophylactic options and expanding global reach of these options, we believe the overall number of addressable patients for our clinical-stage assets, and preclinical and discovery stage programs could be greater than we currently estimate. We aim to establish the industry’s leading coagulation franchise through the execution of our “Hemab 2x3 by 2030” strategic roadmap, which is designed to build a franchise consisting of 2 commercial medicines, 2 new late-stage clinical programs, and 2 new early-stage clinical programs by 2030. We have not yet initiated pivotal trials for any of our product candidates, and due to the novel and unproven nature of our programs, their current stage of development and the lack of approved prophylactic therapies to inform endpoint selection and trial design, we may not be able to achieve our strategic goals on the timeline we expect or at all. Our principal executive offices are located in Cambridge, MA.Fate Therapeutics NASDAQ:FATE$2.25 -0.32 (-12.53%) As of 02:47 PM Eastern This is a fair market value price provided by Massive. Learn more.Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.Harrow NASDAQ:HROW$32.74 -0.13 (-0.38%) As of 02:47 PM Eastern This is a fair market value price provided by Massive. Learn more.Harrow, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc. and changed its name to Harrow Health, Inc. in December 2018. Harrow Health, Inc. was incorporated in 2006 and is headquartered in Nashville, Tennessee.Oculis NASDAQ:OCS$13.19 +0.90 (+7.31%) As of 02:47 PM Eastern This is a fair market value price provided by Massive. Learn more.Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis. The company is based in Zug, Switzerland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palo Alto Networks Accelerates Growth 31% on AI Demand Motorola's $1.5B Bet to Own the Skies Microsoft Build 2026 Is Really Just One Big AI Stress Test Slice of the Pie: Why Yum’s Deal Lifts QSR Urban Outfitters Stock Stalls Despite Another Strong Quarter What IBM's $10-Billion Quantum Project Means For Smaller Players Marvell Stock Soars on NVIDIA's Trillion-Dollar Nod HIVE Earnings Highlight AI Ambitions Beyond Bitcoin Mining Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
